Guggenheim maintains Regeneron Pharmaceuticals at Buy, raises price target to $1100 from $1030
Guggenheim reaffirmed its Buy rating for Regeneron Pharmaceuticals and increased its price target to $1100 from $1030, citing a 6.8% increase. This target suggests an 18.5% upside from the Oct 30 close of $927.89. Recent analyst price targets for the company range from $875 to $1175.
How this was made
The 30-second read
Why it matters
The higher target may attract short‑term buying and support price near current levels.
Market read
A new analyst target can influence trader positioning, especially for a large‑cap biotech like Regeneron.
What to watch
No accompanying earnings or pipeline news; the move may reflect broader market optimism rather than company‑specific catalysts.
Background
Analyst price‑target updates are common after quarterly results, but this note provides a fresh upward revision.
Market effects
May lift biotech sector sentiment modestly.
U.S. market focus on biotech earnings and guidance.
Limited to investors tracking Regeneron and comparable biotech stocks.
Counterpoint
Target raise could be premature without new product data; price may remain flat.
Key entities
- analystGuggenheim
Equity research firm that issued the rating upgrade.
- companyRegeneron Pharmaceuticals
Biotech firm whose stock is the subject of the target raise.
